Targeting self-assembly peptide for inhibiting breast tumor progression and metastasis

Luo, Shuang; Feng, Jiaxing; Xiao, Lirong; Guo, Ling; Deng, Lang; Du, Zhengwu; Yang, Xue; Xu, Song; Sun, Xun; Zhang, Zhirong; Fu, Yao; Gong, Tao

doi:10.1016/j.biomaterials.2020.120055

Cited by 63 publications

(40 citation statements)

References 65 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…provided an alternative HA modified liposomal drug delivery system for inhibiting breast tumor metastasis. [ 79 ] Instead of covalently conjugating HA to the lipids, the HA backbone was coupled with two functional groups, i.e., a cholesterol moiety to be inserted into the lipid bilayer and a peptide moiety that can undergo self‐assembly forming net‐like structures around the tumor cells. This delicate design was proven highly efficient in inhibiting the potential interaction between platelets and tumor cells thus inhibiting distant metastasis ( Figure 7 ).…”

Section: Polysaccharide‐derived Delivery Systems For Inflammation Targetingmentioning

confidence: 99%

Natural Glycan Derived Biomaterials for Inflammation Targeted Drug Delivery

Niu

Xue

2021

Macromolecular Bioscience

Self Cite

View full text Add to dashboard Cite

Inflammation is closely related to a variety of fatal or chronic diseases. Hence, targeting inflammation provides an alternative approach to improve the therapeutic outcome of diseases such as solid tumors, neurological diseases, and metabolic diseases. Polysaccharides are natural components with immune regulation, anti‐virus, anti‐cancer, anti‐inflammation, and anti‐oxidation activities. Herein, this review highlights recent progress in the polysaccharide‐based drug delivery systems for achieving inflammation targeting and its related disease treatment. Moreover, the chemical modification and the construction of polysaccharide materials for drug delivery are discussed in detail.

show abstract

Section: Polysaccharide‐derived Delivery Systems For Inflammation Targetingmentioning

confidence: 99%

Natural Glycan Derived Biomaterials for Inflammation Targeted Drug Delivery

Niu

Xue

2021

Macromolecular Bioscience

Self Cite

View full text Add to dashboard Cite

show abstract

“…Apart from the overexpressed pericellular phosphatase, tumor cells also express specific receptors, including integrin, [19b,55] laminin (LN), [52] CD44, [15] and human epidermal growth factor receptor (HER2) [19a] and enzymes such as carbonic anhydrase IX (CA IX) [18b,56] on cell membranes, which is a reliable foundation for structure-transformable nanogatekeepers for tumor theranostics. Since constitutive HER2 receptor dimerization endows proliferation activation and malignant phenotype survival, Lam and co-workers synthesized a HER2-targeting transformable peptide FFVLK-YCDGFYACYMDV monomer, comprising a reverse β-sheet-forming FFVLK peptide as the self-assembling section, where the anti-HER2/neu peptidic mimic YCDGFYACYMDV segment is linked at the C-terminus and a hydrophobic BP moiety with aggregation-induced emission (AIE) imaging is attached at the N-terminus of the FFVLK sequence.…”

Section: Nanogatekeepers On Tumor Cell Membranesmentioning

confidence: 99%

“…In time, based on the biomedical carriers and specific characteristics of tumor circumstances such as overexpressed receptors [15] on tumor cells or specific microenvironments (e.g., pH, [16] redox state, [17] and enzymes [18] ), several intelligent structure-transformable gated nanosystems (designated nanogatekeeper) have been fabricated. These structure-transformable nanogatekeepers undergo morphological transformation to fibrous nets or enlarged nanoparticle aggregations under a certain specific stimuli in tumor tissue, thus successfully locking nanosystems at the tumor sites instead of backflow into blood circulation.…”

Section: Introductionmentioning

confidence: 99%

Smart Nanogatekeepers for Tumor Theranostics

Zhang

Chen

et al. 2021

Small

View full text Add to dashboard Cite

early tumor mass efficiently, but a single surgical approach seems incompetent for advanced tumor tissues with serious distant metastasis. Surgery cannot completely remove all primary and metastatic tumor cells, thereby generating a high recurrence risk. [2] High-energy radioactive rays are utilized to destroy DNA and protein structures and inhibit there functions in these exposed tumor cells. However, it should be noted that this local irradiationtriggered therapy modality does not distinguish cancer from other tissues, which could induce fatal destruction in circumambient normal tissues. Immunotherapy is an emerging modality that relies on the human immune system and provides a robust defense against advanced and metastatic tumors. [3] Immune checkpoint blockade (ICB) therapy, for example, promotes a systemic immune response that suppresses tumor growth and recurrence by blocking the overexpressed programmed cell death ligand 1 (PD-L1) [4] and CD47 [5] in tumor cells, or cytotoxic T lymphocyte (CTL) associated antigen 4 (CTLA-4) in T cells. [6] Several ICB antibodies, such as pembrolizumab and nivolumab, have been approved by the Food and Drug Administration of the USA (FDA) to treat metastatic colorectal cancer (CRC). [7] Unfortunately, clinical trials revealed that only a fraction of patients with clinical cancer respond to this emerging immunotherapy [8] although this poor efficiency is mainly ascribed to insufficient T cell infiltration [9] and undesirable immunosuppressive microenvironments. [10] Compared to surgery, radiotherapy, and immunotherapy, chemotherapy is preferable as monotherapy or synergetic therapy with the above modalities for cancer treatment. In general, current chemotherapeutic formulations are categorized as solutions and nanoformulations. For example, chemotherapeutic solutions such as Taxel and Doxil are used clinically, but the undesirable selectivity and serious toxicity significantly hinder further application. Compared to solutions, nanoformulations exhibit increased drug accumulation in tumor tissue due to the enhanced permeability and retention (EPR) effect. Specifically, paclitaxel (PTX)-derived Nanoxel shows a higher tumor regression profile than Taxol solution, with improved safety. [11] In addition to EPR-mediated passive accumulation, a liganddirected targeting strategy is also employed in developing nanoparticle (NP) delivery systems as this enables specific ligand-receptor interactions for NP accumulation. [12] To date, numerous tumor microenvironment-sensitive deshielding nanosystems have been fabricated to realize stealth-targeting Nanoparticulate drug delivery systems (nano-DDSs) are required to reliably arrive and persistently reside at the tumor site with minimal off-target side effects for clinical theranostics. However, due to the complicated environment and high interstitial pressure in tumor tissue, they can return to the bloodstream and cause secondary side effects in normal organs. Recently, a number of nanogatekeepers have been engineered via structure-transf...

show abstract

“…A general synthesis method is the wet chemical method in solution via in situ growth of nanocatalysts, followed by designing appropriate surface engineering modifications to confer biocompatibility and multifunctionality. Another approach is the synthesis of various nanocarriers, such as liposomes, [ 30 ] micelles, [ 31 ] exosomes, [ 32 ] MOFs, [ 33 ] in a controlled manner, and then, the loading of drug molecules to produce composite nanocatalysts. The preparation methods for nanocatalysts are listed in Table 1 .…”

Section: Synthesismentioning

confidence: 99%

Which is Better for Nanomedicines: Nanocatalysts or Single‐Atom Catalysts?

Zhao

Zhang

Yang

et al. 2020

Adv Healthcare Materials

View full text Add to dashboard Cite

With the rapid advancements in nanotechnology and materials science, numerous nanomaterials have been used as catalysts for nanomedical applications. Their design and modification according to the microenvironment of diseases have been shown to achieve effective treatment. Chemists are in pursuit of nanocatalysts that are more efficient, controllable, and less toxic by developing innovative synthetic technologies and improving existing ones. Recently, single-atom catalysts (SACs) with excellent catalytic activity and high selectivity have attracted increasing attention because of their accurate design as nanomaterials at the atomic level, thereby highlighting their potential for nanomedical applications. In this review, the recent advances in nanocatalysts and SACs are briefly summarized according to their synthesis, characterizations, catalytic mechanisms, and nanomedical applications. The opportunities and future scope for their development and the issues and challenges for their application as nanomedicine are also discussed. As far as it is known, the review is the systematic comparison of nanocatalysts and SACs, especially in the field of nanomedicine, which has promoted the development of nanocatalytic medicine.

show abstract

Targeting self-assembly peptide for inhibiting breast tumor progression and metastasis

Cited by 63 publications

References 65 publications

Natural Glycan Derived Biomaterials for Inflammation Targeted Drug Delivery

Natural Glycan Derived Biomaterials for Inflammation Targeted Drug Delivery

Smart Nanogatekeepers for Tumor Theranostics

Which is Better for Nanomedicines: Nanocatalysts or Single‐Atom Catalysts?

Contact Info

Product

Resources

About